General Function of the Committee: To provide advice and recommendations to the Agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 3, 2015, from 12:30 p.m. to 5 p.m., and November 4, 2015, from 8 a.m. to 5 p.m.

Location: NCTR SAB, 3900 NCTR Rd., Conference rm. B–12, Jefferson, AR 72079. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

Contact Person: Donna Mendrick, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-796-8892; or FDA Advisory Committee Information Line, 1–800– 741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at http:// www.fda.gov/AdvisoryCommittees/ default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: On November 3, 2015, the SAB Chair will welcome the participants, and the NCTR Director will provide a Center-wide update on scientific initiatives and accomplishments during the past year. The SAB will be presented with an overview of the Division of Biochemistry Subcommittee and the Subcommittee Site Visit Report. Representatives from the Office of the Chief Scientist and Office of Medical Products and Tobacco will discuss research needs and opportunities for collaborations with NCTR.

On November 4, 2015, the Center for Drug Evaluation and Research, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Tobacco Products, Center for Veterinary Medicine, and Office of Regulatory Affairs will each briefly discuss their Center-specific research strategic needs. Following the public session, the SAB will hear an update from each of NCTR's research divisions.

Following an open discussion of all the information presented, the open session of the meeting will close so the SAB members can discuss personnel issues at NCTR at the end of each day.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at http://www.fda.gov/ AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee meeting link.

Procedure: On November 3, 2015, from 12:30 p.m. to 5 p.m., and November 4, 2015, from 8 a.m. to 4:15 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before October 27, 2015. Oral presentations from the public will be scheduled between approximately 11:45 a.m. and 12:45 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 19, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by October 20, 2015.

Closed Committee Deliberations: On November 4, 2015, from 4:15 p.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to permit discussions of information concerning individuals associated with the research programs at NCTR.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Donna Mendrick at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 10, 2015.

Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2004-N-0451; formerly Docket No. 2004N-0226]

Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 040

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing a
publication containing modifications
the Agency is making to the list of
standards FDA recognizes for use in
premarket reviews (FDA Recognized
Consensus Standards). This publication,
entitled "Modifications to the List of
Recognized Standards, Recognition List
Number: 040" (Recognition List
Number: 040), will assist manufacturers
who elect to declare conformity with
consensus standards to meet certain
requirements for medical devices.

DATES: Submit electronic or written comments concerning this document at any time. See section VII for the effective date of the recognition of standards announced in this document.

ADDRESSES: An electronic copy of Recognition List Number: 040 is available on the Internet at *http://*

www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
Standards/ucm123792.htm. See section
VI for electronic access to the searchable
database for the current list of FDA
recognized consensus standards,
including Recognition List Number: 040
modifications and other standards
related information.

Submit written requests for a single hard copy of the document entitled "Modifications to the List of Recognized Standards, Recognition List Number: 040" to the Division of Industry and Consumer Education, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4613, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your request, or fax your request to 301–847–8149.

Submit electronic comments on this document to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Scott A. Colburn, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 3632, Silver Spring, MD 20993, 301–796–6287, standards@cdrh.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

Section 204 of the Food and Drug Administration Modernization Act of 1997 (Pub. L. 105–115) amended section 514 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360d). Amended section 514 allows FDA to recognize consensus standards developed by international and national organizations for use in satisfying portions of device premarket review submissions or other requirements.

In a notice published in the Federal Register of February 25, 1998 (63 FR 9561), FDA announced the availability of a guidance entitled "Recognition and Use of Consensus Standards." The notice described how FDA would implement its standard recognition program and provided the initial list of recognized standards.

Modifications to the initial list of recognized standards, as published in the **Federal Register**, can be accessed at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Standards/ucm123792.htm.

These notices describe the addition, withdrawal, and revision of certain standards recognized by FDA. The Agency maintains HTML and PDF versions of the list of FDA Recognized Consensus Standards. Both versions are publicly accessible at the Agency's

Internet site. See section VI for electronic access information. Interested persons should review the supplementary information sheet for the standard to understand fully the extent to which FDA recognizes the standard.

II. Modifications to the List of Recognized Standards, Recognition List Number: 040

FDA is announcing the addition, withdrawal, correction, and revision of certain consensus standards the Agency will recognize for use in premarket submissions and other requirements for devices. FDA will incorporate these modifications in the list of FDA Recognized Consensus Standards in the Agency's searchable database. FDA will use the term "Recognition List Number: 040" to identify these current modifications.

In table 1, FDA describes the following modifications: (1) The withdrawal of standards and their replacement by others, if applicable; (2) the correction of errors made by FDA in listing previously recognized standards; and (3) the changes to the supplementary information sheets of recognized standards that describe revisions to the applicability of the standards.

In section III, FDA lists modifications the Agency is making that involve the initial addition of standards not previously recognized by FDA.

TABLE 1—MODIFICATIONS TO THE LIST OF RECOGNIZED STANDARDS

Old recognition No.	Replacement recognition No.	Title of standard ¹	Change
		A. Anesthesia	
1–46	1–103	ISO 5367 Fifth edition 2014–10–15 Anaesthetic and respiratory equipment—Breathing sets and connectors.	Withdrawn and replaced with newer version.
1–82		IEC 60601–2–13 Edition 3.1 2009–08, Medical electrical equipment— Part 2–13: Particular requirements for the safety and essential per- formance of anaesthetic systems.	Withdrawn. See 1–104.
		B. Biocompatibility	
2–179	2–220	ISO 10993–1 Fourth edition 2009–10–15 Biological evaluation of medical devices—Part 1:. Evaluation and Testing within a risk management process [Including: Technical Corrigendum 1 (2010)].	Withdrawn and replaced with newer version including Tech- nical Corrigendum.
2–208	2–215	, ,,,	Withdrawn and replaced with newer version.
2–209	2–216	USP 38–NF33:2015 <87> Biological Reactivity Test, In Vitro—Elution Test.	Withdrawn and replaced with newer version.
2–210	2–217	USP 38–NF33:2015 <88> Biological Reactivity Tests, In Vivo, Procedure Preparation of Sample.	Withdrawn and replaced with newer version.
2–211	2–218		Withdrawn and replaced with newer version.
2–212	2–219	USP 38–NF33:2015 <88> Biological Reactivity Tests, In Vivo, Classification of Plastics—Systemic Injection Test.	Withdrawn and replaced with newer version.

TARIF 1_	-MODIFICATIONS TO THE	LIST OF RECOGNIZED	STANDARDS—Continued
I ADLL I		LIST OF TILGOGINIZED	OTANDANDS—CONTINUED

	IADELI	WODINGATIONS TO THE EIST OF TRESOURIZED STANDARDS	Continued	
Old recognition No.	Replacement recognition No.	Title of standard ¹	Change	
		C. Cardiovascular		
3–76		ASTM F2129–08 Standard Test Method for Conducting Cyclic Potentiolognamic Polarization Measurements to Determine The Cor-	Transferred. See 8–177.	
3–117		rosion Susceptibility of Small Implant Devices. ANSI/AAMI/ISO 81060–2:2013 Non-invasive sphygmomanometers— Part 2: Clinical validation of automated measurement type.	Extent of recognition.	
3–122		ISO 81060-2 Second edition 2013-05-01 Non-invasive sphygmomanometers—Part 2: Clinical validation of automated measurement type.	Extent of recognition.	
	1	D. Dental/Ear, Nose, and Throat (ENT)		
4–105		ANSI/ADA Standard No.75 (Reaffirmed by ANSI: September 8, 2014) Resilient Lining Materials For Removable Dentures, Part 1: Short- Term Materials.	Reaffirmation.	
4–130		ANSI/ADA Standard No. 17 (Reaffirmed by ANSI: September 8, 2014) Denture Base Temporary Relining Resins.	Reaffirmation.	
4–150		ANSI/ADA Specification No. 19–2004/ISO 4823:2000 (Reaffirmed by ANSI: October 6, 2014) Dental Elastomeric Impression Materials.	Reaffirmation.	
4–184		ANSI/ASA S3.25–2009 (Revision of ANSI S3.25–1989) (Reaffirmed by ANSI September 11, 2014) American National Standard For an Occluded Ear Simulator.	Reaffirmation.	
4–191	4–220		Withdrawn and replaced with newer version.	
		E. General I (Quality Systems/Risk Management (QS/RM))		
5–67		ANSI/AAMI/IEC 62366:2007/(R)2013 Medical devices—Application of usability engineering to medical devices.	Withdrawn. See 5-96.	
5–87		IEC 62366 Edition 1.1 2014–01 Medical devices—Application of usability engineering to medical devices.	Withdrawn. See 5-95.	
5–94		AAMI/CN20 (PS):2014 Small-bore connectors for liquids and gases in healthcare applications—Part 20: Common test methods.	Withdrawn. See 5–97.	
	F	F. General II (Electrical Safety/Electromagnetic Compatibility (ES/EMC		
19–6		IEC 60601–1–11 Edition 1.0 2010–04 Medical Electrical Equipment— Part 1–11: General Requirements for Basic Safety and Essential Performance—Collateral Standard: Requirements for Medical Electrical Equipment and Medical Electrical Systems used in the Home Healthcare Environment [Including: Technical Corrigendum 1 (2011)].	 - -	
		G. General Hospital/General Plastic Surgery (GH/GPS)		
6–110		ASTM F1441-03 (Reapproved 2014) Standard Specification for Soft-	Reaffirmation.	
6–185		Tissue Expander Devices. ASTM F881 – 94 (Reapproved 2014) Standard Specification for Sili-	Reaffirmation.	
6–200		cone Elastomer Facial Implants. ASTM E1061–01 (Reapproved 2014) Standard Specification for Direct-Reading Liquid Crystal Forehead Thermometers.	Reaffirmation.	
6–274	6–341	ISO 11608–1 Third Edition 2014–12–15 Needle-based injection systems for medical use—Requirements and test methods—Part 1: Needle-based injection systems.	Withdrawn and replaced with newer version.	
6–301		ISO 10555–1 Second Edition 2013–07–01 Sterile, single-use intravascular catheters—Part 1: General requirements.	Extent of Recognition.	
6–308	6–342	IEC 80601–2–35 Edition 2.0 2009–10 Medical electrical equipment— Part 2–35: Particular requirements for the basic safety and essential performance of heating devices using blankets, pads or mattresses and intended for heating in medical use [Including: Technical Corrigendum 1 (2012) and Technical Corrigendum 2 (2015)].	Withdrawn and replaced with newer version including Technical Corrigendum.	
6–326	6–343	USP 38–NF 33:2015 Sodium Chloride Irrigation	Withdrawn and replaced with newer version.	
6–327	6–344	USP 38–NF 33:2015 Sodium Chloride Injection	Withdrawn and replaced with newer version.	
6–328	6–345	USP 38–NF33:2015 Nonabsorbable Surgical Suture	Withdrawn and replaced with newer version.	
6–329	6–346	USP 38–NF33:2015 <881> Tensile Strength	Withdrawn and replaced with newer version.	

TABLE 1—MODIFICATIONS TO THE LIST OF RECOGNIZED STANDARDS—Continued

Old recognition No.	Replacement recognition No.	Title of standard ¹	Change		
6–330	6–347	USP 38–NF33:2015 <861> Sutures—Diameter	Withdrawn and newer version.	replaced	with
6–331	6–348	USP 38–NF33:2015 <871> Sutures—Needle Attachment	Withdrawn and newer version.	replaced	with
6–332	6–349	USP 38–NF33:2015 Sterile Water for Irrigation	Withdrawn and newer version.	replaced	with
6–333	6–350	USP 38-NF33:2015 Heparin Lock Flush Solution	Withdrawn and newer version.	replaced	with
6–334	6–351	USP 38–NF33:2015 Absorbable Surgical Suture	Withdrawn and newer version.	replaced	with
		H. In Vitro Diagnostics (IVD)	I		
7–110	7–251	CLSI EP05–A3 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Third Edition.	Withdrawn and	replaced	with
7–143	7–252	CLSI EP14–A3 Evaluation of Matrix Effects; Approved Guideline— Third Edition.	newer version. Withdrawn and newer version.	replaced	with
7–153	7–253	CLSI EP15–A3 User Verification of Performance for Precision and Estimation of Bias; Approved Guideline-Third Edition.	Withdrawn and newer version.	replaced	with
7–230	7–254	CLSI M07–A10 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard—Ninth Edition.	Withdrawn and newer version.	replaced	with
7–123	7–255	CLSI MM09–A2 Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline—Second Edition.	Withdrawn and newer version.	replaced	with
7–247	7–256	CLSI M100–S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement.	Withdrawn and newer version.	replaced	with
	1	I. Materials	,		
8–59	8–386	ISO 5832–4 Third edition 2014–09–15 Implants for surgery—Metallic materials—Part 4: Cobalt-chromium-molybdenum casting alloy.	Withdrawn and version.	replaced	newer
8–63	8–387	ISO 5832-11 Second edition 2014-09-15 Implants for surgery—Metallic materials—Part 11: Wrought titanium 6-aluminium 7-niobium	Withdrawn and newer version.	replaced	with
8–177		alloy. ASTM F2129–08 Standard Test Method for Conducting Cyclic Potentiodynamic Polarization Measurements to Determine the Corrosion Susceptibility of Small Implant Devices.			
	1	J. Neurology			
17–9		ASTM F2129–08 Standard Test Method for Conducting Cyclic Potentiodynamic Polarization Measurements to Determine the Corrosion Susceptibility of Small Implant Devices.			
17–4		ASTM F647–94(2014) Standard Practice for Evaluating and Specifying Implantable Shunt Assemblies for Neurosurgical Application.	Reaffirmation.		
	K. Obst	etrics-Gynecology-Urology-Gastroenterology (OB–GYN–GU)/Gastroe	nterology		
9–73	9–104	ANSI/AAMI/ISO 13958:2014 Concentrates for hemodialysis and related therapies.	Withdrawn and newer version.	replaced	with
9–97		ISO 13958 Third edition 2014–04–01 Concentrates for haemodialysis	Extent of recognition	on.	
9–69	9–105	and related therapies. ANSI/AAMI 13959:2014 Water for hemodialysis and related therapies	Withdrawn and	replaced	with
9–100		ISO 11663 Second edition 2014–04–01 Quality of dialysis fluid for haemodialysis and related therapies.	newer version. Extent of recognition	on.	
9–71	9–106	ANSI/AAMI/ISO 11663:2014 Quality of dialysis fluid for hemodialysis and related therapies.	Withdrawn and newer version.	replaced	with
9–70	9–107	ANSI/AAMI 23500:2014 Guidance for the preparation and quality management of fluids for hemodialysis and related therapies.	Withdrawn and newer version.	replaced	with
9–102		ISO 4074 Second edition 2014–08–15 Natural latex rubber condoms— Requirements and test methods.	Extent of recognition		
9–90	9–108	ISO 8009 Second edition 2014–11–15 Mechanical contraceptives— Reusable natural and silicone rubber contraceptive diaphragms— Requirements and tests.	Withdrawn and newer version.	replaced	with
9–56	9–109	ASTM D3492–08 Standard Specification for Rubber Contraceptives (Male Condoms).	Withdrawn and newer version.	replaced	with

TABLE 1—MODIFICATIONS TO THE LIST OF RECOGNIZED STANDARDS—Continued

	Г		I		
Old recognition No.	Replacement recognition No.	Title of standard ¹	Cha	ınge	
		L. Ophthalmic			
10–29	10–94	ISO 14730 Second edition 2014–10–01 Ophthalmic Optics—Contact lens care products—antimicrobial preservative efficacy testing and	Withdrawn and newer version.	replaced	with
10–55	10–95	guidance on determining discard date. ISO 11979–6 Third edition 2014–10–01 Ophthalmic implants—intra- ocular lenses—Part 6: Shelf-life and transport stability.	Withdrawn and newer version.	replaced	with
10–62	10–96	ANSI Z80.10–2014 American National Standard for Opthalmics Ophthalmic Instruments—Tonometers.	Withdrawn and newer version.	replaced	with
10–68	10–97	ISO 13212 Third edition 2014–09–01 Ophthalmic Optics-Contact lens care products—Guidelines for determination of shelf-life.	Withdrawn and newer version.	replaced	with
10–82	10–98	ISO 11979–2 Second edition 2014–08–15 Ophthalmic implants—Intra- ocular lenses—Part 2: Optical properties and test methods.	Withdrawn and newer version.	replaced	with
		M. Orthopedic			
11–240	11–287	ASTM F382–14 Standard Specification and Test Method for Metallic Bone Plates.	Withdrawn and version.	replaced	newer
11–235	11–288	ASTM F2077–14 Test Methods for Intervertebral Body Fusion Devices	Withdrawn and newer version.	replaced	with
11–207	11–289	ASTM F2193–14 Standard Specifications and Test Methods for Components Used in the Surgical Fixation of the Spinal Skeletal System.	Withdrawn and newer version.	replaced	with
11–183		ASTM F1875–98 (Reapproved 2014) Standard Practice for Fretting Corrosion Testing of Modular Implant Interfaces: Hip Femoral Head-Bore and Cone Taper Interface.	Reaffirmation.		
11–266		ASTM F2665–09 (Reapproved 2014) Standard Specification for Total Ankle Replacement Prosthesis.	Reaffirmation.		
11–224		ASTM F2706–08 (Reapproved 2014) Standard Test Methods for Occipital-Cervical and Occipital-Cervical-Thoracic Spinal Implant Con-	Reaffirmation.		
11–80	11–290	structs in a Vertebrectomy Model ISO 8828 Second edition 2014–11–15 Implants for surgery—Guidance on Care and Handling of Orthopaedic Implants.	Withdrawn and newer version.	replaced	with
11–248	11–291	ISO 14242–1 Third edition 2014–10–15 Implants for surgery—Wear of total hip-joint prostheses—Part 1: Loading and displacement parameters for wear testing machines and corresponding environmental conditions for test.	Withdrawn and newer version.	replaced	with
11–250	11–292	ISO 14243–3 Second edition 2014–11–01 Implants for surgery—Wear of total knee prostheses—Part 3: Loading and displacement parameters for wear—testing machines with displacement control and corresponding environmental conditions for test.	Withdrawn and newer version.	replaced	with
		N. Radiology			
12–102		ANSI/IESNA RP-27.2-2000 (Reaffirmed 2011) Photobiological Safety	Reaffirmation.		
12–212	12–289	for Lamp & Lamp Systems-Measurement Techniques. IEC 62220–1–1 Edition 1.0 2015–03 Medical electrical equipment— Characteristics of digital x-ray imaging devices—Part 1–1: Determination of the detective quantum efficiency—Detectors used in radiographic imaging.	Withdrawn and newer version.	replaced	with
12–229	12–290	IEC 61910-1 Edition 1.0 2014-09 Medical electrical equipment—Radiation dose documentation—Part 1: Radiation dose structured re-	Withdrawn and newer version.	replaced	with
12–278	12–291	ports for radiography and radioscopy. IEC 62127–2 Edition 1.1 2013–02 Ultrasonics Hydrophones—Part 2: Calibration for ultrasonic fields up to 40 MHz.	Withdrawn and newer version.	replaced	with
		O. Sterility			
14–193	14–457	ANSI/AAMI/ISO 11607–1:2006/(R)2010 Packaging for terminally sterilized medical devices—Part 1: Requirements for materials, sterile	newer version	replaced including A	
14–194	14–458	barrier systems and packaging [Including: Amendment 1 (2014)]. ANSI/AAMI/ISO 11607–2:2006/(R)2010 Packaging for terminally sterilized medical devices—Part 2: Validation requirements for forming,	newer version	replaced including A	
14–195	14–459	sealing and assembly processes[Including: Amendment 1 (2014)]. ANSI/AAMI/ISO 11140–1:2014 Sterilization of health care products— Chamical indicators—Part 1: Caparal requirements	ment. Withdrawn and	replaced	with
14–287		Chemical indicators—Part 1: General requirements. ANSI/AAMI/ISO 11737–2:2009/(R)2014 Sterilization of medical devices—Microbiological methods—Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process.	newer version. Reaffirmation.		

TABLE 1—MODIFICATIONS TO THE LIST OF RECOGNIZED STANDARDS—Continued

Old recognition No.	Replacement recognition No.	Title of standard ¹	Char	nge	
14–297	14–461	ANSI/AAMI/ISO 11137–1:2006/(R) 2010 Sterilization Of Health Care Products—Radiation—Part 1: Requirements For Development, Validation, And Routine Control Of A Sterilization Process For Medical Devices [Including: Amendment 1 (2013)].	Withdrawn and newer version i ment.		with mend-
14–300	14–462	ASTM D4169—14 Standard Practice for Performance Testing of Shipping Containers and Systems.	Withdrawn and newer version.	replaced	with
14–327		ISO 11737–2 Second edition 2009–11–15 Sterilization of medical devices—Microbiological methods—Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process.	Extent of Recognit	ion.	
14–350		ANSI/AAMI/ISO 13408–4:2005/(R)2014, Aseptic processing of health care products—Part 4: Clean-in-place technologies.	Reaffirmation.		
14–353	14–460	ISO 11140–1 Third edition 2014–11–01 Sterilization of health care products—Chemical indicators—Part 1: General requirements.	Withdrawn and newer version.	replaced	with
14–391	14–463	ISO/ASTM 51608 Third edition 2015–03–15 Practice for dosimetry in an X-ray (bremsstrahlung) facility for radiation processing at energies between 50 KeV and 7.5 MeV.	Withdrawn and newer version.	replaced	with
14–392	14–464	ISO/ASTM 51649 Third edition 2015–03–15 Practice for dosimetry in an electron beam facility for radiation processing at energies between 300 keV and 25 MeV.	Withdrawn and newer version.	replaced	with
14–431	14–465	ISO/ASTM 51707 Third edition 2015–03–15 Guide for estimation of measurement uncertainty in dosimetry for radiation processing.	Withdrawn and newer version.	replaced	with
14–440	14–466	USP 38–NF33:2015 <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests.	Withdrawn and newer version.	replaced	with
14–441	14–467	USP 38–NF33:2015 <71> Sterility Tests	Withdrawn and newer version.	replaced	with
14–442	14–468	USP 38-NF33:2015 <85> Bacterial Endotoxins Test	Withdrawn and newer version.	replaced	with
14–443	14–477	USP 38–NF33:2015 <151> Pyrogen Test (USP Rabbit Test)	Withdrawn and newer version.	replaced	with
14–444	14–469	USP 38–NF33:2015 <161> Transfusion and Infusion Assemblies and Similar Medical Devices.	Withdrawn and newer version.	replaced	with
14–445	14–470	USP 38–NF33:2015 Biological Indicator for Steam Sterilization—Self Contained.	Withdrawn and newer version.	replaced	with
14–446	14–471	USP 38–NF33:2015 Biological Indicator for Dry-Heat Sterilization, Paper Carrier.	Withdrawn and newer version.	replaced	with
14–447	14–472	USP 38–NF33:2015 Biological Indicator for Ethylene Oxide Sterilization, Paper Carrier.	Withdrawn and newer version.	replaced	with
14–448	14–473	USP 38-NF33:2015 Biological Indicator for Steam Sterilization, Paper Carrier.	Withdrawn and newer version.	replaced	with
14–449	14–474	USP 38–NF33:2015 <62> Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms.	Withdrawn and newer version.	replaced	with
14–450	14–475	USP 38–NF33:2015 <55> Biological Indicators—Resistance Performance Tests.	Withdrawn and newer version.	replaced	with
14–451	14–476	USP 38–NF33:2015 <1035> Biological Indicators for Sterilization	Withdrawn and newer version.	replaced	with

¹ All standard titles in this table conform to the style requirements of the respective organizations.

III. Listing of New Entries

In table 2, FDA provides the listing of new entries and consensus standards

added as modifications to the list of recognized standards under Recognition List Number: 040.

TABLE 2—New Entries to the List of Recognized Standards

Recognition No.	Title of standard ¹	Reference No. and date
	A. Anesthesia	
1–104	Medical electrical equipment—Part 2–13: Particular Requirements for basic safety and essential performance of an anaesthetic workstation [Including: Amendment 1 (2015)].	
1–105	Medical electrical equipment—Part 2–72: Particular requirements for basic safety and essential performance of home healthcare environment ventilators for ventilator-dependent patients.	

TABLE 2—New Entries to the List of Recognized Standards—Continued

Recognition No.	Title of standard 1	Reference No. and date
	B. Biocompatibility	
2–221 2–222	Biological Evaluation of Medical Devices: Part 2—Animal Welfare Requirements Biological Evaluation of Medical Devices: Part 2—Animal Welfare Requirements	ANSI/AAMI/ISO 10993-2:2006 (R2014). ISO 10993-2 Second edition 2006-07- 15.
	C. Cardiovascular	-
3–135	Cardiovaccular implants and extraographical evotage. Vaccular device drug com-	ISO/TS 12417-1 First edition 2011-06-
3–136	Cardiovascular implants and extracorporeal systems—Vascular device-drug combination products. Cardiovascular implants and extracorporeal systems—Vascular device-drug com-	01. ANSI/AAMI/ISO TIR12417:2011.
	bination products.	ANSI/AAWI/130 TIN12417.2011.
3–137 3–138	Standard Guide for Testing Absorbable Stents	ASTM F3036-13. ASTM F2942-13.
3–139	Active implantable medical devices—Electromagnetic compatibility—EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices.	ISO 14117 First edition 2012–07–15.
	D. General I (Quality Systems/Risk Management)	
5–95	Medical devices—Part 1: Application of usability engineering to medical devices	IEC 62366-1 Edition 1.0 2015-02.
5–96	Medical devices—Part 1: Application of usability engineering to medical devices	ANSI/AAMI/IEC 62366-1:2015.
5–97	Small-bore connectors for liquids and gases in healthcare applications—Part 20: Common test methods.	ISO 80369–20 First edition 2015–05–15.
	E. General II (ES/EMC)	
19–14	Medical electrical equipment—Part 1–11: General requirements for basic safety and essential performance—Collateral Standard: Requirements for medical electrical equipment and medical electrical systems used in the home healthcare environment.	IEC 60601-1-11 Edition 2.0 2015-01.
19–15	Medical electrical equipment—Part 1–12: General requirements for basic safety and essential performance—Collateral Standard: Requirements for medical electrical equipment and medical electrical systems intended for use in the emergency medical services environment.	IEC 60601-1-12 Edition 1.0 2014-06.
	F. GH/GPS	
6–352 6–353 6–354	Standard Specification for Implantable Breast Prostheses	ASTM F2051 – 00 (Reapproved 2014).
	G. IVD	
7–257	Principles and procedures for Detection of Anaerobes in Clinical Specimens; Approved Guideline.	CLSI M56-A.
7–258	Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standards- Twelfth Edition.	CLSI M02-A12.
	H. Materials	
8–388	Implants for surgery—Ceramic materials—Part 2: Composite materials based on a high-purity alumina matrix with zirconia reinforcement.	ISO 6474–2 First edition 2012–04–15.
8–389	Implants for surgery—Differential scanning calorimetry of poly ether ether ketone (PEEK) polymers and compounds for use in implantable medical devices.	ISO 15309 First edition 2013–12–01.
8–390	Standard Specification for Semi-Crystalline Poly(lactide) Polymer and Copolymer Resins for Surgical Implants.	ASTM F1925-09.
8–391	Standard Specification for Poly(glycolide) and Poly(glycolide-co-lactide) Resins for Surgical Implants with Mole Fractions Greater Than or Equal To 70% Glycolide.	ASTM F2313-10.
	I. Nanotechnology	
18–4	Technical Specification—Nanotechnologies—Vocabulary—Part 6: Nano-object characterization.	ISO/TS 80004–6 First edition 2013–11- 01.
	J. Neurology	

TABLE 2—NEW ENTRIES TO THE LIST OF RECOGNIZED STANDARDS—Continued

	TABLE 2—NEW ENTRIES TO THE LIST OF RECOGNIZED STANDARD	os—Continued		
Recognition No.	Title of standard 1	Reference No. and date		
	K. OB-GYN-GU/Gastroenterology			
9–103	Water treatment equipment for hemodialysis and related therapies	ANSI/AAMI 26722:2014.		
	L. Ophthalmic			
10–99	Anionic and non-ionic surface active agents—Determination of critical micellization concentration—Method by measuring surface tension with a plate, stirrup, or ring,.			
	M. Orthopedic			
11–293 11–294 11–295	Standard Test Method for Impingement of Acetabular Prostheses	ASTM F2582-14. ASTM F1357-14. ASTM F2580-13.		
	N. Physical Medicine			
16–194	Wheelchairs Part 25:Batteries and chargers for powered wheelchairs	ISO 7176–25 First edition 2013–07–15.		
	O. Radiology			
12–292	IEEE Recommended Practice for Three-Dimensional (3D) Medical Modeling	IEEE Std 3333.2.1–2015.		
	P. Software/Informatics			
13–73	Systematized Nomenclature of Medicine—Clinical Terms	IHTSDO SNOME-CT RF2 Release		
13–74	Health informatics—Personal health device communication, Part 10424: Device Specialization—Sleep Apnoea Breathing Therapy Equipment (SABTE).	IEEE Std 11073-10424-2014.		
13–75	Health informatics—Point-of-care medical device communication—Part 10102: Nomenclature—Annotated ECG.	ISO/IEEE 11073–10102 First edition 2014–03–01.		
13–76	Health informatics—Standard communication protocol—Part 91064: Computer-as-	ISO 11073-91064 First edition 2009-		
13–77	sisted electrocardiography. Information technology—Security techniques—Vulnerability disclosure	05-01. ISO/IEC 29147 First edition 2014-02-		
13–78	Information technology—Security techniques—Vulnerability handling processes	15. ISO/IEC 30111 First edition 2013–11- 01.		
	Q. Sterility	,		
14–478	Flexible and semi-rigid endoscope processing in health care facilities	ANSI/AAMI ST91:2015.		

¹ All standard titles in this table conform to the style requirements of the respective organizations.

IV. List of Recognized Standards

FDA maintains the Agency's current list of FDA Recognized Consensus Standards in a searchable database that may be accessed directly at FDA's Internet site at http:// www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfStandards/search.cfm. FDA will incorporate the modifications and revisions described in this notice into the database and, upon publication in the Federal Register, this recognition of consensus standards will be effective. FDA will announce additional modifications and revisions to the list of recognized consensus standards, as needed, in the Federal Register once a year, or more often if necessary. Beginning with Recognition List 033, FDA no longer announces minor revisions to the list of recognized consensus standards such as technical contact person, devices affected,

processes affected, Code of Federal Regulations citations, and product codes.

V. Recommendation of Standards for Recognition by FDA

Any person may recommend consensus standards as candidates for recognition under section 514 of the FD&C Act by submitting such recommendations, with reasons for the recommendation, to standards@ *cdrh.fda.gov.* To be properly considered, such recommendations should contain, at a minimum, the following information: (1) Title of the standard, (2) any reference number and date, (3) name and address of the national or international standards development organization, (4) a proposed list of devices for which a declaration of conformity to this standard should routinely apply, and (5) a brief

identification of the testing or performance or other characteristics of the device(s) that would be addressed by a declaration of conformity.

VI. Electronic Access

You may obtain a copy of "Guidance on the Recognition and Use of Consensus Standards" by using the Internet. The Center for Devices and Radiological Health (CDRH) maintains a site on the Internet for easy access to information including text, graphics, and files that you may download to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page, http://www.fda.gov/ MedicalDevices, includes a link to standards-related documents including the guidance and the current list of recognized standards. After publication in the Federal Register, this notice announcing "Modification to the List of

Recognized Standards, Recognition List Number: 040" will be available at http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
Standards/ucm123792.htm. You may access "Guidance on the Recognition and Use of Consensus Standards," and the searchable database for "FDA Recognized Consensus Standards" at http://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
Standards.

VII. Submission of Comments and Effective Date

Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http:// www.regulations.gov. FDA will consider any comments received in determining whether to amend the current listing of modifications to the list of recognized standards, Recognition List Number: 040. These modifications to the list of recognized standards are effective upon publication of this notice in the Federal Register.

Dated: August 10, 2015.

Leslie Kux,

Associate Commissioner for Policy.
[FR Doc. 2015–19991 Filed 8–13–15; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-D-0386]

Establishing the Performance
Characteristics of In Vitro Diagnostic
Devices for the Detection or Detection
and Differentiation of Human
Papillomaviruses; Draft Guidance for
Industry and Food and Drug
Administration Staff: Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled "Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses." This draft guidance provides recommendations to facilitate study designs to establish the performance characteristics of in vitro diagnostic devices (IVDs) intended for the detection, or detection and differentiation, of human papillomaviruses (HPVs). This draft guidance is not final nor is it in effect at this time.

DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment of this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance November 12, 2015.

ADDRESSES: An electronic copy of the guidance document is available for download from the Internet. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the guidance. Submit written requests for a single hard copy of the draft guidance document entitled "Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses" to the Office of the Center Director, Guidance and Policy Development, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send one selfaddressed adhesive label to assist that office in processing your request.

Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

Natalia Comella, Center for Devices and Radiological Health, Food and Drug Administration, New Hampshire Ave., Bldg. 66, Rm. 4536, Silver Spring, MD 20993–0002, 301–796–6226, Natalia.Comella@fda.hhs.gov, or Marina V. Kondratovich, Center for Devices and Radiological Health, Food and Drug Administration, New Hampshire Ave., Bldg. 66, Rm. 4672, Silver Spring, MD 20993–0002, 301–796–6036, Marina.Kondratovich@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

This draft guidance provides recommendations to facilitate study designs to establish the performance characteristics of IVDs intended for the detection, or detection and differentiation, of HPVs. These devices are used either in conjunction with cervical cytology to aid in screening for cervical cancer or as first-line primary cervical cancer screening devices. These devices include those that detect a group of HPV genotypes, particularly high risk HPVs, as well as devices that detect more than one genotype of HPV and further differentiate among them to indicate which genotypes of HPV are present.

When finalized, this draft guidance is expected to provide detailed information on the types of studies the FDA recommends to support a premarket application for these devices. This draft guidance specifically addresses devices that qualitatively detect HPV nucleic acid from cervical specimens, but many of the recommendations will also be applicable to devices that detect HPV proteins. The draft guidance is limited to studies intended to establish the performance characteristics of in vitro diagnostic HPV devices that are used in conjunction with cervical cytology for cancer screening or as first-line primary cervical cancer screening devices. This draft guidance does not address HPV testing from non-cervical specimens such as pharyngeal, vaginal, penile, or anal specimens, or testing for susceptibility to HPV infection. It does not address quantitative or semiquantitative assays for HPV.

II. Significance of Guidance

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on evaluating the performance characteristics of IVDs intended for the detection, or detection and differentiation, of HPVs. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statute and regulations.

III. Electronic Access

Persons interested in obtaining a copy of the draft guidance may do so by downloading an electronic copy from the Internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at http://www.regulations.gov. Persons